Skip to main content
main-content

14.09.2015 | Onkologie | Onlineartikel

Immunotherapy: effective treatments gathering on the horizon

EGFR mutations and ALK rearrangements are well-established therapeutic targets in NSCLC, with EGFR TKIs and ALK TKIs representing the first-line standard of care for these molecular subsets of patients. However, resistance to first-generation inhibitors invariably develops, which calls for strategies to improve upon the durability of any response. Moreover, targeted agents are available only for a limited group of patients, while chemotherapy with or without anti-angiogenic treatments still remains the cornerstone in the majority of cases. Docetaxel is the standard second-line therapy in NSCLC, but its use is hampered by important toxicity.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten